A multi-center clinical trial for establishing the screening algorithm and preoperative imaging diagnostic criteria of small Hepatocellular carcinoma (less than 10 mm)

A multi-center, randomized, parallel groups, comparing the diagnostic performance of extracellular agent contrast MRI, hepatobiliary specific agent contrast MRI, with ultrasonography for screening and characterizing micro (less than 10mm) Hepatocellular Carcinoma (micro-HCC) and establishing the consensus preoperative di

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036201

Enrollment

Unknown

Registered

2020-08-21

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

US+ Extracellular agent MRI group:Extracellular agent MRI screening

US+Hepatobiliary specific agent MRI group:Hepatobiliary specific agent MRI screening

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hepatitis B virus infection; 2. and(or) Hepatitis C virus infection; 3. Alcoholism; 4. non-alcoholic steatosis hepatitis; 5. long-term exposure to aflatoxin polluted food; 6. other causes of cirrhosis, a family history of hepatocellular carcinoma.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with HCC; 2. Patients with a prior history of TACE, RFA, or chemotherapy; 3. Allergic to MRI contrast agents; 4. Patients with claustrophobia.

Design outcomes

Primary

Measure	Time frame
Alpha-fetoprotein;DCP;CEA;AFP-L3;Micro-RNA;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactZeng Mengsu

Fudan University affiliated Zhongshan Hospital

zeng.mengsu@zs-hospital.sh.cn+86 13501922963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026